Views & Analysis Nine for 2019: how did we do on our predictions, and what do... Year-ends prompt reflection, both on what’s happened in the last 12 months and on the year ahead.
Views & Analysis Nine for 2019: Opportunities for pharma In the last Nine for 2019 article, we reflected on the major challenges that are sha
Views & Analysis Nine for 2019: Challenges impacting pharma As we move close to 2019’s halfway point, it’s time to reflect on the issues that are shaping the pharmaceutical industry for this year and beyond.
News After setback, Rhythm gets good news on Imcivree from FDA Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
